Abstract
D isproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium a , a ,1 b ,2 c a NO to form peroxynitrite, which can cause protein nitralethargy, peripheral edema). Age-matched Wistar-Furth tion [7] . The latter mechanism reduces NO bioavailability, rats and 10-week-old LBN-F1 rats served as controls. thereby limiting cardiovascular effects of this compound.
Since none of the functional parameters determined exPerez et al. reported that treatment of trabeculae isolated hibited any significant difference between the two control from nonfailing or stunned rat hearts with a cocktail of the rat groups, data from both groups were pooled for statisti-XO-inhibitor allopurinol and the ?OH scavenger N- (2- cal analysis. Animals were anesthetized by intraperitoneal mercaptopropionyl)-glycine (MPG) substantially improved injection of sodium pentobarbital (|50 mg) and hearts 21 contractility by enhancing Ca responsiveness [8] . Requickly removed and mounted for retrograde perfusion placing allopurinol with oxypurinol (synonym: alloxanwith a high-potassium (20 mM) modified Krebs-Henseleit thine), the active metabolite of allopurinol that blocks XO (K-H) solution, equilibrated with 95% O / 5% CO , 4 4 3 that hemodynamic function was only slightly [10] , if at all 7.37-7.43. Trabeculae were microdissected from the right [11] , improved after i.v. administration of allopurinol to ventricles and mounted in a superfusion bath between a nonfailing animals. In dogs with rapid ventricular pacingforce transducer (type AE 801, SensoNor, Horten, Norinduced heart failure, however, the inotropic effects afway) and a hook connected to a micromanipulator for forded by allopurinol were unambiguous, and contractile length adjustment. All measurements were carried out at efficiency was enhanced [10, 11] . The observed improveroom temperature (22-23 8C) . Preparations were super-
21
ments of contractile function and myocardial efficiency fused at 10 ml min with the same K-H solution except 1 2 were associated with enhanced XO activity in failing dog for [K ] 5 mM and [Cl ] 127 mM and excited by bipolar myocardium, compared to nonfailing controls [10] . In electrical field stimulation, amplitude 5-10 V, pulse width human patients with idiopathic dilated cardiomyopathy, 5 ms (Grass SD9 Stimulator; Grass Instruments, Quincy, intracoronary infusion of allopurinol likewise increased MA, USA), at 0.5 Hz. After equilibration, muscles were myocardial efficiency [12] , an effect which consisted of stretched to the length at which developed twitch tension markedly reduced oxygen consumption in the face of a was maximal (L ty. Lean male SHHF rats heterozygous for the fa OR, USA) was microinjected iontophoretically into 3-5 (corpulent) gene, which encodes a defective leptin recells of each preparation and allowed to spread evenly ceptor, exhibit arterial hypertension and eventually develop throughout the preparation via gap junctions [17] . Fura-2 CHF as a consequence of chronic pressure overload at fluorescence was excited at 340 and 380 nm, and the about 18 months of age [13] . SHHF-rat myocardium emitted light signal was collected at 510 nm by a photo- 21 exhibits defective Ca cycling and contractile dysfunction multiplier tube (R2693, Hamamatsu, Bridgewater, NJ, [14] as well as excitation-contraction coupling abnor-USA), filtered at 100 Hz, collected by an A / D converter, malities [15] resembling those present in human CHF. A and stored on a computer for subsequent analysis. Raw preliminary report of this work has appeared [16] .
fluorescence data were corrected for autofluorescence and 21 [Ca ] was calculated using the following equation [18] : treated groups, oxypurinol was present from onset of half-maximal tension development, and n is the Hill perfusion of the excised heart, which was maintained for coefficient. The relative magnitudes of inotropic effects in 15 min before starting to dissect a trabecula, and through-SHHF and failing preparations were compared after norout the entire experiment. In the drug-free groups, an malizing the tension data from oxypurinol-treated preparaaliquot of solvent (1 M NaOH) was added at the same tions with respect to the mean absolute tension of the time.
respective drug-free group under the same conditions. Statistical significance was assessed using unpaired Stu-2 .4. Measurement of xanthine oxidase /xanthine dent's t-test. P,0.05 was considered statistically signifioxidoreductase activity cant. Pooled data are expressed as means6S.E.M.
XO / XOR activity in tissue homogenates was determined using a fluorometric assay measuring the conversion of pterin to isoxanthopterin [20] . At 345 nm excitation, 3 . Results formation of isoxanthopterin can be monitored by the increase in fluorescence emitted at 390 nm. Tissue samples 3 .1. Effects of oxypurinol on contractility in failing of 25-50 mg were obtained from the free right ventricular myocardium wall immediately prior to dissection of a trabecula for force measurement, shock-frozen in liquid N , and stored Hearts of SHHF rats (n513) were enlarged, and all but 2 at 280 8C until use. In oxypurinol-treated preparations, one animal showed pleural effusions, liver congestion, and hearts had been exposed to 100 mM oxypurinol for 15 min ascites, while such clinical signs of heart failure were prior to collection of the samples. Frozen samples were completely absent in control rats (n516). Body weight homogenized in 1:4 (w / v) of ice-cold HEPES buffer (10 showed a tendency to decrease in SHHF compared to mM) containing sucrose (320 mM), DTT (1 mM), leupepage-matched control rats (461644 vs. 6826113 g, respectin (10 mg / ml), soybean trypsin inhibitor (10 mg / ml), tively, P5n.s.). Both heart weight:body weight and lung aprotinin (2 mg / ml), EDTA (0.1 mM) and PMSF (0.1 weight:body weight ratios were significantly increased in mM), and centrifuged at 13 000 rpm for 35 min at 4 8C.
SHHF, compared to age-matched control rats ( Fig. 1 ), Reducing conditions and the presence of protease inindicating severe myocardial hypertrophy and lung congeshibitors are required to prevent spontaneous conversion of tion. These parameters were similar in SHHF rats assigned XDH to XO. Baseline was measured after mixing the to the oxypurinol-treated or drug-free groups, indicating supernatant (25 ml) with KH PO buffer (50 mM, pH 7.2) comparable severity of heart failure. 2 4 in a quartz cuvette. XO activity was calculated from the We simultaneously examined calcium cycling and tenslope of the linear increase in fluorescence obtained during sion development during twitches of intact right ventricular 2 min following the addition of the substrate, pterin (10 trabeculae from drug-free and oxypurinol-treated SHHF rat mM). Then, methylene blue (10 mM), which is used as an electron acceptor by XDH, was added and the subsequent increase in fluorescence over time was used to calculate the combined activities of XO and xanthine dehydrogenase (XDH) (total XOR activity). The reaction was stopped by the addition of allopurinol (50 mM). For calibration, the step change in fluorescence intensity upon addition of a standard concentration of isoxanthopterin was measured. 21 21 Values are expressed as pmol min mg protein , with protein concentrations determined using the Lowry protein assay (Bio-Rad).
.5. Data analysis and statistics
All force values were normalized to the cross-sectional area of each muscle (width3thickness3p / 4) and are (Fig. 3A) . Nevertheless, twitch tension
We carried out the same experimental protocol in i was significantly enhanced in oxypurinol-treated preparaisolated trabeculae from nonfailing rat hearts. Original , respectively, compared to drug-free failing trabeculae (n58 in both the drug-free and oxypurinol-treated groups), (n55; Fig. 3B ). Neither the time from peak tension to half treatment with 100 mM oxypurinol did not significantly 21 21 relaxation exhibit the slow kinetics typically observed in failing myocardium. While the Ca -transient amplitude is similar, developed twitch tension is substantially higher in the oxypurinol-treated preparation. higher than in drug-free muscles (n58 in each group), while in oxypurinol-treated trabeculae from SHHF rats 21 (n54) the increase in maximum Ca -activated tension was 75.0614.3% compared to drug-free preparations (n5 5). Thus, the fractional increase in tension was 3-fold greater in failing than in nonfailing myocardium (P5 21 0.036). Maximum Ca -activated tension in drug-free SHHF preparations (n55) was 4168% of that developed by drug-free nonfailing preparations (n58), indicating severe contractile dysfunction in the failing group. Oxypurinol-treated preparations (n54), on the other hand, 21 exhibited a maximum Ca -activated tension equaling 72612% of that developed on average by drug-free nonfailing control trabeculae (n58). Thus, although oxypurinol treatment resulted in substantial improvement of contractility in failing myocardium, contractile function still remained impaired compared to drug-free nonfailing myocardium (P50.007).
.4. Xanthine oxidase /xanthine oxidoreductase activity
We determined tissue XO and XOR activity in right ventricular homogenates from drug-free failing and nonfailing hearts as well as failing hearts treated with oxypurinol (Fig. 8) . The total XOR activity (i.e. combined XO and XDH activities) in RV from drug-free failing SHHF rat hearts (n58) was significantly enhanced compared to control myocardium (n55) (P50.044; Fig. 8A ). XO activity tended to be almost 2-fold higher in failing (n58) than in nonfailing myocardium (n55) (P50.07; Fig. 8B ). Both XOR and XO activities were largely suppressed in 21 oxypurinol-treated SHHF rat myocardium (n55) ( In the present study, treatment of rat failing and nonfailing isolated myocardium with the XO inhibitor 21 Filled symbols, drug-free failing myocardium (n55); open symbols, oxypurinol-treated failing myocardium (n54). Maximum Ca -activated tension is 21 increased without alterations in Ca sensitivity. Invisible error bars indicate that error is smaller than the symbol. P value indicates difference between the mean maximum isometric tension values. Ca transient amplitude is similar, the oxypurinol-treated preparation develops higher twitch tension. However, the oxypurinol-induced enhancement of contractility is less pronounced than in the failing group. study, or from the use of oxypurinol rather than the parent notion that XO-inhibition exerts positive inotropic effects compound allopurinol, but this was not tested here.
by increasing NO bioavailability. Pretreatment of dogs Nevertheless, the central finding remains an enhancement with the nonisoform specific NOS inhibitor, L-NMMA, on 21 in myofilament Ca responsiveness with XO-inhibitor the other hand, completely abolished the inotropic and treatment, resulting in a positive inotropic effect unaccomenergy-sparing effects of allopurinol [23] , indicating that 2 panied by a rise in activator calcium. These inotropic reducing ?O formation alone was not sufficient to 2 effects of oxypurinol were qualitatively similar in failing improve contractile function. Furthermore, exogenously and nonfailing myocardium. We found, however, contracapplied peroxynitrite reduced contractility in isolated rat tility to be improved to a markedly greater extent in cardiac myocytes [24] . Taken together, these studies point preparations from failing hearts.
to peroxynitrite as a potential culprit in the impairment of In order to understand this apparent 'selectivity' for force generation and energetic efficiency in CHF models. failing myocardium one needs to consider potential mechaThus, it is conceivable that improvement of contractile nisms mediating the inotropic effects exerted by oxyfunction by oxypurinol is due to its property of inhibiting purinol: Apart from their XO-inhibitory properties, al-XO. If this is the case, the magnitude of the inotropic lopurinol and oxypurinol are direct (albeit weak) ?OH effect will be affected by the level of XO activity scavengers [21] . Furthermore, other presently unidentified accessible to blockade by XO-inhibitors. Consistent with direct actions of the drug on the myofibrillar proteins could this hypothesis, intravenous administration of allopurinol 21 account for the enhancement of myofilament Ca responsubstantially improved hemodynamic function and ener-2 siveness observed here and previously [8] . Elevated ?O getic efficiency in dogs suffering from rapid ventricular 2 levels are found in failing myocardium, and both mitopacing-induced CHF, while in nonfailing control dogs an chondria and xanthine oxidase have been implicated in only minor inotropic effect was detectable [10, 11] . These 2 their generation [4] . ?O and NO react with each other, differential effects were associated with enhanced XO 2 thereby forming peroxynitrite. Therefore, inotropic effects activity in failing dog myocardium, compared to nonfailing of XO inhibition could either result from reduced genecontrols [10] . Elevation of myocardial xanthine oxido-2 ration of ?O or peroxynitrite, or from increased bioavailreductase activity has been described in several rat CHF 2 ability of NO. In dogs with pacing-induced heart failure, models, e.g. monocrotaline-induced right ventricular failblockade of myocardial iNOS-dependent NO formation ure and postmyocardial infarction failure [25] . In the increased cardiac output [22] , which argues against the present study, we used a different model of heart failure in dium), while other studies testing the effects of allopurinol in vivo found only subtle effects in nonfailing controls. A critical aspect when considering these differences may be the species used. In failing dog myocardium XO activity was about 5-fold that exhibited by failing myocardium [10] , while in our study using rat the difference was only 2-fold. Higher intrinsic XO activity in the nonfailing rat myocardium, compared with dog, could be an explanation.
The presence of higher XO activity in nonfailing rat myocardium, in turn, could explain why XO inhibition results in greater improvement of contractility in control rat myocardium. This was, however, not tested here, and a study directly comparing XO expression in rat and dog to our knowledge has not yet been published. Another substantial difference between this and previous studies is that we, for the first time, report a difference in the extent of inotropic effects of XO-inhibition between failing and nonfailing hearts at the level of the isolated myocardium. When allopurinol is applied in vivo [10, 11] , vascular effects of XO-inhibition may have interfered with the observed improvement of hemodynamic parameters. XO inhibitors enhance nitric oxide (NO)-dependent vasodilation, presumably due to an increase in NO bioavail-2 ability subsequent to reduction in ?O levels [26] [27] [28] . 2 Thus, when hemodynamic parameters are being assessed as a measure of cardiac contractile function, changes in intrinsic myocardial contractility on the one hand and in pre-and / or afterload on the other hand may have offset each other. Moreover, the vascular response to oxypurinol is augmented under conditions of increased oxidative stress, which was discussed to be due to increased endog- The present study identifies an important action of 21 8). Oxypurinol has no effect on Ca cycling but significantly increases oxypurinol, which is magnified in the failing myocardium, force development. Invisible error bars indicate that error is smaller than but information regarding the biochemical basis of these symbol; n.s., not significant. effects remains to be obtained. Release of endogenous catecholamines from intracardiac stores does not seem to play a role, since in this case an increase in tension the rat, the spontaneous hypertensive / heart failure rat. development would be accompanied by a considerable rise Failing animals had significantly higher levels of XOR [Ca ] transient kinetics, which we did not observe in this activity tended to be considerably enhanced. The inotropic i study. It is clear from previous work that the effects of XO action of oxypurinol was more pronounced in failing than inhibition are tied to NO metabolism, since nonisoform in nonfailing myocardium, and this improvement of conspecific inhibition of NOS abolished the inotropic effects tractile function was associated with nearly complete of allopurinol in vivo [23] . We selected a concentration of suppression of the elevated XO / XOR activity by oxypurinol in the failing group. We have no reason to assume oxypurinol (100 mM) readily achieved in human patients that the XO / XOR-inhibitory action of oxypurinol might treated for gout with 300 mg of allopurinol [30] . Since the differ between groups, although we did not test whether effects of NO are known to be biphasic, it would certainly XO / XOR activity was suppressed to a similar extent by be logical and worthwhile to test whether lower conoxypurinol in the nonfailing group.
centrations of the XO inhibitor (e.g. 10 and 30 mM) exert a An interesting question remains as to why in our study qualitatively similar and graded response. However, such nonfailing myocardium showed a clear inotropic response experiments are beyond the scope of the present study, to XO inhibition (albeit weaker than in the failing myocarwhose major purpose was to establish the preferential 21 21 Fig 
